Iroko   Report issue

For profit Phase 2 Phase 3
Founded: Philadelphia PA United States (2007)
Status: No NME R&D (2007)

Organization Overview

First Clinical Trial
2009
NCT00964431
First Marketed Drug
2015
meloxicam (mobic)
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Iroko Pharmaceuticals, LLC

Active Ingredients

Marketed Drugs (1)

meloxicam (mobic) (2015)

Drugs in Phase 3 Trials (4)

celecoxib (celebrex) (4 trials)

diclofenac (voltaren) (5 trials)

indomethacin (indocin) (4 trials)

meloxicam (mobic) (3 trials)

Drugs in Phase 2 Trials (1)

naproxen (naprosyn) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Pain, Postoperative (Phase 3)

Toothache (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 5